Home > Insider Trading > Filing (0001012975-13-000125)

Filing Details

Accession Number:: 0001012975-13-000125
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-03-28 17:07:38
Reporting Period:: 2013-03-26

Filing Date:: 2013-03-28
Accepted Time:: 2013-03-28 17:07:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1177648	Enanta Pharmaceuticals Inc	ENTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1106929	Tvm Iv Gmbh & Co Kg	C/O Tvm Capital Group Maximilianstrasse 35C Munich 2M 80539	No	No	Yes	No
1133935	Tvm Medical Ventures Gmbh & Co Kg	C/O Tvm Capital Group Maximilianstrasse 35C Munich 2M 80539	No	No	Yes	No
1183073	Tvm V Life Science Ventures Gmbh & Co Kg	C/O Tvm Capital Croup Maximilianstrasse 35C Munich 2M 80539	No	No	Yes	No
1342938	Tvm V Life Science Ventures Management Gmbh & Co. Kg	C/O Tvm Capital Group Maximilianstrasse 35 C Munich 2M 80539	No	No	Yes	No
1342939	Gmbh Capital Tvm	C/O Tvm Capital Group Maximilianstrasse 35C Munich 2M 80539	No	No	Yes	No
1342940	Tvm Iv Management Gmbh & Co. Kg	C/O Tvm Capital Group Maximilianstrasse 35C Munich 2M 80539	No	No	Yes	No
1397372	Alexandra Goll	C/O Tvm Capital Group Maximilianstrasse 35C Munich 2M 80539	No	No	Yes	No
1398596	Stefan Fischer	C/O Tvm Capital Group Maximilianstrasse 35C Munich 2M 80539	No	No	Yes	No
1398598	Hubert Birner	C/O Tvm Capital Group Maximilianstrasse 35C Munich 2M 80539	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-03-26	236,065	$0.00	236,065	No	4	C	Direct
Common Stock	Acquisiton	2013-03-26	351,014	$0.00	351,014	No	4	C	Direct
Common Stock	Acquisiton	2013-03-26	155,316	$0.00	391,381	No	4	C	Direct
Common Stock	Acquisiton	2013-03-26	172,030	$0.00	523,044	No	4	C	Direct
Common Stock	Acquisiton	2013-03-26	1,006,498	$0.00	1,006,498	No	4	C	Direct
Common Stock	Acquisiton	2013-03-26	478,247	$0.00	1,484,745	No	4	C	Direct
Common Stock	Acquisiton	2013-03-26	132,949	$14.00	1,617,694	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Convertible Preferred Stock	Disposition	2013-03-26	1,017,442	$0.00	236,065	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2013-03-26	1,130,000	$0.00	351,014	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2013-03-26	500,000	$0.00	155,316	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2013-03-26	563,503	$0.00	172,030	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2013-03-26	3,296,888	$0.00	1,006,498	$0.00
Common Stock	Series G-2 Convertible Preferred Stock	Disposition	2013-03-26	2,061,246	$0.00	478,247	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

The Series C Convertible Preferred Stock automatically converted into Enanta Pharmaceuticals, Inc. ("Enanta") Common Stock on a 0.23202-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.
The Series D Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.31063-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.
The Series E Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.30529-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.
The Series G-2 Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.23202-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.
The shares are directly held by TVM Medical Ventures GmbH & Co. KG ("Medical Ventures"), the general partner of which is TVM Capital GmbH ("TVM Capital"), for which Alexandra Goll ("Goll"), one member of the investment committee of TVM Capital, shares voting and investment authority over the shares held by Medical Ventures with the other member of the investment committee. Each of TVM Capital and Goll disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.
The shares are directly held by TVM IV GmbH & Co. KG ("TVM IV"), the managing limited partner of which is TVM IV Management GmbH & Co. KG ("TVM IV Management"), for which Goll, one member of the investment committee of TVM IV Management, shares voting and investment authority over the shares held by TVM IV with the other members of the investment committee. Each of TVM IV Management and Goll disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.
The shares are directly held by TVM V Life Science Ventures GmbH & Co. KG ("TVM V"), the managing limited partner of which is TVM V Life Science Ventures Management GmbH & Co. KG ("TVM V Management"), for which Hubert Birner ("Birnner"), Stefan Fischer ("Fischer") and Goll, each a member of the investment committee of TVM V Management, shares voting and investment authority over the shares held by TVM V. Each of TVM V Management, Birner, Fischer and Goll disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.